LBCTR2021034768已完成未知
In vivo evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against salivary SARS-CoV-2 - N/A
ebanese University0 个研究点目标入组 77 人开始时间: 2021年3月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 12 至 100（—）
- 性别
- All
入选标准
- •COVID-19 Positive Tested Patients in Rafik Hariri University Hospital, Beirut, Lebanon, presenting mild or moderate symptoms and who (or guardians) give written informed consent.
排除标准
- •1- COVID-19 Positive Tested Patients presenting severe cases.
- •2- COVID-19 Positive Tested Patients presenting disabilities (Mental retardation-Physical invalidity-Psychological,troubles- Cognitive troubles affecting the capacity of discernation).
- •3- Patients (or guardians) who decline written informed consent.
研究者
相似试验
已完成
不适用
An evaluation of the effect of chlorhexidine in combination with sodium perborate on gingivitis, plaque and tooth surface stainingCondition 1: gingivitis. Condition 2: tooth surface staining.Chronic gingivitisPosteruptive colour changes of dental hard tissuesIRCT201102245900N1Hamedan dental faculty40
进行中（未招募）
不适用
A pilot study of the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19ISRCTN13447477Royal Surrey County Hospital NHS Foundation Trust22
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)EUCTR2008-003538-11-CZBoehringer Ingelheim RCV GmbH & Co. KG700
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)Proposed new title:Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double blinded, randomised, placebo controlled, Phase II)EUCTR2008-003538-11-PTBoehringer Ingelheim Pharma GmbH & Co. KG700
进行中（未招募）
1 期
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).EUCTR2008-003538-11-FRBoehringer-Ingelheim France420